Navigation Links
Nile Therapeutics Announces Dosing of First Heart Failure Patient in Phase Ib Study of CD-NP
Date:2/6/2008

BERKELEY, Calif., Feb. 6 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (OTC Bulletin Board: NILT), today announced that the first heart failure patient has been dosed in its Phase Ib, multi-center, open-label, ascending dose clinical study of the company's lead product candidate, CD-NP, a novel chimeric natriuretic peptide, in development for the treatment of acute decompensated heart failure.

"We are very excited that dosing has begun in this important dose- escalation study of CD-NP in heart failure patients," said Peter Strumph, Chief Executive Officer of Nile. "CD-NP has the potential to fill a large unmet medical need in the treatment of heart failure. This trial provides us our first opportunity to assess the drug's activity in heart failure patients, and to further build on our understanding of the molecule's mechanism of action."

The primary objectives of the study are to assess the safety and tolerability of intravenous infusions of CD-NP in patients with heart failure. Safety assessments include measurement of blood pressure, heart rate, serum potassium and kidney function as calculated by glomerular filtration rate (GFR). Clinical assessments include urine flow rate, sodium excretion rate and plasma cGMP, a secondary messenger of the target receptor. The trial is expected to enroll up to approximately 35 patients. Results from the trial are expected to be available in 2008.

About CD-NP

CD-NP is a rationally-designed synthetic peptide that combines selected components of naturally occurring natriuretic peptides to create a novel, NPR- B agonist which has a favorable pharmacological profile with potent renal enhancement and cardiac unloading properties, but minimal hypotensive effects. Data from Nile's recently completed Phase Ia study in 22 healthy volunteers was consistent with several pre-clinical findings, including that CD-NP was associated with increased levels of plasma cGMP, a secondary messenger of the target
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Cell Therapeutics, Inc. (CTI) Cuts Net Operating Expenses 35% and Expands Commercial Team to Support Zevalin(R) Sales and Applications Seeking Two Product Approvals in 2009
2. Prime Therapeutics Becomes First PBM to Join the Center for Health Value Innovation
3. Reckitt Benckiser Completes Acquisition of Adams Respiratory Therapeutics, Inc.
4. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at Merrill Lynch 19th Global Pharmaceutical, Biotechnology & Medical Device Conference in New York City
5. Allos Therapeutics Appoints Bruce K. Bennett as Vice President, Manufacturing
6. Ocera Therapeutics Receives Orphan Drug Status for AST-120 for Pouchitis
7. Transition Therapeutics Announces Appointment of Vice-President of Business Development
8. Cell Therapeutics, Inc. (CTI) Completes Acquisition of Lymphoma Drug Zevalin(R) From Biogen Idec for Sales and Marketing in the United States
9. Transition Therapeutics Announces Milestone Payment from Elan
10. ImaRx Therapeutics Submits Urokinase Data to FDA Supporting Extended Expiration Dating
11. Reckitt Benckiser Commences Cash Tender Offer for All Outstanding Shares of Adams Respiratory Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/8/2009)...SNewswire/ -- The Pew Charitable Trusts announced ...chemical and food safety programs, in its Health &... formerly deputy staff director and general counse...c Works, brings nearly 25 years of experience in e... , , "We are excited to be joined by such an ex...
(Date:1/8/2009).... Christine Siu and Jason Brown, Ph.D. Promoted t... and STAMFORD, Conn., Jan. 8 Thoma...capital firm that invests in life science and medi...otion of three members of its investment team. Ka...e Siu and Jason Brown have been promoted to Vice P...
(Date:1/8/2009)...-USNewswire/ -- A proposal by the State of Indiana...n,s Home has prompted the 125,000-member American ...Mid-Winter conference January 10-12, 2009, in orde...nanimous opposition to the proposal. , , The Le... direct and in-kind support to the home, is among ...
(Date:1/8/2009)...e/ -- The physicians of Northern Lake Medical,Ltd...orthern Illinois,communities, announced today tha... (Photo: http://www.newscom.com/cgi-bin/prnh/2...ine physicians serve patients through clinics in,... and Fox Lake. , "The Northern Lake Medical...
Breaking Medicine News(10 mins):Health News:Veteran Environmental Health Expert Erik D. Olson to Join Pew 2Health News:Thomas, McNerney & Partners Promotes Three Members of Its Investment Team 2Health News:Northern Lake Medical to Join Aurora Health Care 2Health News:Northern Lake Medical to Join Aurora Health Care 3
...se Priya Ranjan Dasmunsi, Information and Broadcas...roved for a six million dollar scheme to join the ...C). It helps to prevent and improve cancer treat...ll help in the development of cancer vaccine in In...
... found that the fear of death before voting had an... Analyses of Social Issues and Public policy repor...004 presidential election in US. Researchers felt ...tape before the election had an impact on the psyc...
... the University of California have now established...ons, garlic, beans, carrot, corn, dark leafy// veg...isk by as much as 50%. The study is based on inter...ts and 1, 700 controls. The new research has been ...
...Hund and her team from University of Illinois have...derwent sexual abuse during their childhood. Eatin... psychological stress and depression in earlier st...ave published the results of their work in the Jou...
Other Medicine News:
(Date:1/8/2009)...n an ongoing Phase Ib trial demonstrated a 2.5 log..., Conference Call Today at 8:30AM EST , , SAN...armaceuticals, Inc. (Nasdaq: ANDS ) today announ...ase Ib clinical trial of ANA598, the Company,s inv... ANA598 was very well-tolerated and demonstrated p...
(Date:1/7/2009)...ewswire/ -- Scientists have identified mutations i... in children with acute lymphoblastic leukemia (AL...research is needed to determine how changes in the...a relapse, the findings are likely to provide the ...sk of treatment failure. By using a molecular test...
(Date:1/7/2009)... ImQuest Life Sciences announced today the success...nd Drug Administration to initiate human clinical ...r IQP-0410. ImQuest anticipates initiating their P...410 is a novel small molecule inhibitor of HIV whi...criptase inhibitor (NNRTI). The compound possesses...
(Date:1/7/2009)...n Puhua Hospital Stem Cells Center ( http://www.st...stem cells to effectively treat neurological disor... additions to its medical and research staff that ...bilities for growing numbers of incoming internati...distinguished Dr. Jiang Ping, who was named Chief ...
Breaking Medicine Technology:ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 2ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 3ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 4ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 5ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 6Gene Abnormality Found to Predict Childhood Leukemia Relapse 2Gene Abnormality Found to Predict Childhood Leukemia Relapse 3Gene Abnormality Found to Predict Childhood Leukemia Relapse 4Gene Abnormality Found to Predict Childhood Leukemia Relapse 5Gene Abnormality Found to Predict Childhood Leukemia Relapse 6ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410 2Stem Cell Treatment Leader Tiantan Puhua Adds Experienced International Medical Staff for Expanding Numbers of Patients 2Stem Cell Treatment Leader Tiantan Puhua Adds Experienced International Medical Staff for Expanding Numbers of Patients 3Sharps Compliance Corp Announces Appointment of Al Aladwani as its Senior Vice President of Operations 14951 1Sharps Compliance Corp Announces Appointment of Al Aladwani as its Senior Vice President of Operations 14951 2Sharps Compliance Corp Announces Appointment of Al Aladwani as its Senior Vice President of Operations 14951 3Risky teen behavior may not occur at home or school 3A but how to track 3F 14948 1Risky teen behavior may not occur at home or school 3A but how to track 3F 14948 2China Medical Technologies Receives CE Mark for Two ECLIA Analyzers and 15 Reagents 14944 1China Medical Technologies Receives CE Mark for Two ECLIA Analyzers and 15 Reagents 14944 2CMPMedica Expands SearchMedica com with Multiple Additional Vertical Search Applications co developed with Convera 28R 29 4144 1CMPMedica Expands SearchMedica com with Multiple Additional Vertical Search Applications co developed with Convera 28R 29 4144 2CMPMedica Expands SearchMedica com with Multiple Additional Vertical Search Applications co developed with Convera 28R 29 4144 3
...E)--Jul 5, 2007 - Array BioPharma Inc.,(Nasdaq: AR...er,Robert E. Conway, will speak at the C.E Unterb...n New York City. The public is,welcome to particip...ay BioPharma website. -0-, ,Event: C.E Un...er: Robert E. Conway, Chief Executive Officer...
...UNSWICK, New Jersey, July 03, 2007,/PRNewswire-Fir...NA,company, announced today that J. Michael French...nterberg, Towbin Emerging Growth,Opportunities Con...e Mandarin Oriental Hotel in New York. , A live au...on,the "Investors" section of the company,s websit...
Other Medicine Technology:Rosetta Genomics to Webcast Presentation at CE Unterberg, Towbin,Emerging Growth Opportunities Conference 2
Central platform with integrated neck. Piston assembly fits into neck of platform utilizing an internal spring to recoil to ready position after use. Cutting block fits into precision milled cavity i
TLS Surgical Markers allows the surgeon to effectively diagram incision sites with a scrub-resistant, gentian violet ink. All TLS Surgical Markers are provided sterile, with a ruler and are individua
Periosteal elevator, freer.
The Surgifoam* absorbable gelatin sponge, U.S.P. is a sterile, water-insoluble, malleable, porcine gelatin absorbable sponge intended for hemostatic use by applying to a bleeding surface. The sponge
Medicine Products: